Chalfont St Giles, UK and Wuhan, China – 25 September 2013 – GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE), and JHL Biotech, a provider of biopharmaceutical process development and manufacturing services, today announced that a KUBio™ modular biopharmaceutical factory will be built in China for JHL Biotech. The site for the new factory, which will be fully operational beginning early 2015, is the Biolake Science Park in Wuhan, China.
Worldwide demand for biopharmaceuticals, such as antibodies for the treatment of cancer and a new generation of innovative vaccines, is increasing dramatically. KUBio is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility. Pre-designed to meet cGMP requirements, KUBio helps manufacturers, such as JHL Biotech, respond to local healthcare needs and support global customers in bringing life-saving treatments to market more quickly.
GE Healthcare’s innovative turnkey approach will involve the assembly at the JHL Biotech site in Wuhan, China of pre-made modules equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals. In addition to GE project-managing the build, members of its experienced Shanghai Fast Trak team will be deployed to validate the equipment and provide training for JHL Biotech staff. After completion, the JHL Biotech KUBio facility will have a floor space of approximately 2,400m2 and will contain a number of 2,000L single-use bioreactors.
Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences, commented, “The decision of JHL Biotech’s highly experienced team to select KUBio as the basis of its commercial cGMP biopharmaceutical manufacturing capabilities in China is a fantastic endorsement of our complete, turnkey approach. We look forward to working with them to bring the facility online to serve the fast-moving biopharmaceutical industry. A diverse range of customers, including governments and pharmaceutical companies, are continuing to recognise the breadth, depth, simplicity and flexibility of what we offer with KUBio.“
Racho Jordanov, Co-founder, President and CEO of JHL Biotech, added, “In realising our vision of making world-class biopharmaceuticals affordable and accessible to all patients, KUBio was the natural choice. Utilizing manufacturing innovations was always a key part of our strategy and GE Healthcare’s KUBio delivers the technologies we want, with the technical support and training we need.”
KUBio is the latest addition to GE Healthcare’s broad offering of world-class tools, technologies and services for the biopharmaceutical manufacturing industry, allowing customers to benefit from a wide range of solutions that can be tailored to meet specific needs, from pilot to commercial scale. KUBio aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About JHL Biotech
JHL Biotech is an emerging biopharmaceuticals company founded by a group of biotech veterans with decades of manufacturing experience and backed by a consortium of top-tier venture capital firms including Kleiner Perkins Caufield & Byers China Fund, Sequoia Capital, Burrill & Co and China Development Industrial Bank (CBID). The vision of the company is to provide world-class process development and manufacturing services to companies developing and commercializing high-quality, affordable biologic medicines. A key component in achieving this vision is to build and operate state-of-the-art facilities in compliance with United States, European Union and International Conference on Harmonisation (ICH) current good manufacturing practices (cGMP) regulations and guidelines. JHL Biotech, together with GE, has already completed facilities in Taiwan to support all pre-clinical and early clinical activities for biologics development; facilities to support commercial manufacturing in Wuhan, China will be completed in early 2015. With this comprehensive infrastructure in place, JHL Biotech is uniquely positioned to deliver manufacturing solutions to its worldwide partners. For more information about the company, visit our website at www.jhlbiotech.com.
About Biolake Science Park
Biolake, one of the most important industrial parks for biopharmaceuticals in China, has been developing rapidly. Currently, nearly 80 companies with more than 100 projects covering all stages of drug development, including R&D, pilot testing, production and services, are clustered in the park. Biolake has become an important R&D center and production base in China for biotech drug development. For more information about Biolake, visit our website at en.biolake.org
Dr. Val Jones, Global Media Relations Manager
T +44 7917 175 192
Dr. William Shen, VP, Business Development
T +86 27 87879208